News

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.
Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...
With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...
Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...
Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.
Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.
[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...
Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...
Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, ...
Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.
Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine , 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 Cite This Page : ...